Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for AQST.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -2.591M
March 31, 2026 4.423M
December 31, 2025 0.66M
September 30, 2025 81.41M
June 30, 2025 -0.10M
March 31, 2025 20.65M
December 31, 2024 0.157M
September 30, 2024 -0.017M
June 30, 2024 1.711M
March 31, 2024 81.74M
December 31, 2023 3.913M
September 30, 2023 4.979M
June 30, 2023 4.287M
March 31, 2023 -9.205M
December 31, 2022 0.204M
September 30, 2022 -0.138M
June 30, 2022 10.20M
March 31, 2022 1.298M
December 31, 2021 5.454M
Date Value
September 30, 2021 6.078M
June 30, 2021 8.686M
March 31, 2021 9.891M
December 31, 2020 28.49M
September 30, 2020 -0.007M
June 30, 2020 0.01M
March 31, 2020 -0.037M
December 31, 2019 39.07M
September 30, 2019 13.63M
June 30, 2019 -0.493M
March 31, 2019 -2.609M
December 31, 2018 4.687M
September 30, 2018 63.74M
June 30, 2018 -4.206M
March 31, 2018 -1.417M
December 31, 2017 -0.567M
September 30, 2017 -0.043M
June 30, 2017 0.00
March 31, 2017 5.024M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
LENZ Therapeutics, Inc. 0.395M
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M
Veru, Inc. -0.0519M
Johnson & Johnson -8.777B